200 related articles for article (PubMed ID: 20874254)
1. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
van Beers MM; Jiskoot W; Schellekens H
J Interferon Cytokine Res; 2010 Oct; 30(10):767-75. PubMed ID: 20874254
[TBL] [Abstract][Full Text] [Related]
2. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis.
Bendtzen K
J Interferon Cytokine Res; 2010 Oct; 30(10):759-66. PubMed ID: 20874253
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
[TBL] [Abstract][Full Text] [Related]
4. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
5. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
6. [The methods of detection of binding and neutralizing antibodies to preparations of interferon-beta].
Nazarov VD; Lapin SV; Surkova EA; Makshakov GS; Mazing AV; Evdoshenko EP; Totolian AA
Klin Lab Diagn; 2016 Oct; 61(10):710-4. PubMed ID: 30615336
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Horowski R; Stürzebecher CS; Kapp JF
Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
[No Abstract] [Full Text] [Related]
10. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
11. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
[TBL] [Abstract][Full Text] [Related]
12. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs.
Gibbs E; Karim ME; Oger J;
Clin Immunol; 2015 Mar; 157(1):91-101. PubMed ID: 25543089
[TBL] [Abstract][Full Text] [Related]
13. [Neutralizing antibodies in patients with multiple sclerosis treated with interferon beta-1b].
Río J; Barberà N; Tintoré M; Brieva L; Montalbán X
Med Clin (Barc); 2000 Feb; 114(5):169-70. PubMed ID: 10738721
[TBL] [Abstract][Full Text] [Related]
14. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
15. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
Seres E; Vécsei L
Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
[TBL] [Abstract][Full Text] [Related]
16. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
17. Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
Hartung HP; Munschauer FE
J Neurol; 2004 Jun; 251 Suppl 2():II40-2. PubMed ID: 15264111
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
[TBL] [Abstract][Full Text] [Related]
20. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Núñez C; Cénit MC; Alvarez-Lafuente R; Río J; Fernández-Arquero M; Arroyo R; Montalbán X; Fernández O; Oliver-Martos B; Leyva L; Comabella M; Urcelay E
J Med Genet; 2014 Jun; 51(6):395-400. PubMed ID: 24748646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
